STAFF BOARD
Article
CHAIRMAN
Manuela Velázquez Prieto
EDITOR IN CHIEF
Jaime E. Poquet Jornet
MARKETING MANAGER
EDITORIAL BOARD
Tomás Casasín Edo
Virginia Hernández Corredoira
Ramón Jódar Masanés
Juan Carlos Juárez Giménez
Volume 20 - Issue 5, September-October 2018
ORIGINAL
TEDUGLUTIDE TREATMENT IN A SHORT BOWEL SYNDROME
BELLVER ALBERTOS MARTA, MONTERO HERNÁNDEZ MÓNICA, MEDINA GUERRERO ÁLVARO, GIL BORRAS RAFAEL, SOLER COMPANY ENRIQUE


Teduglutide, was approved for adult patients with short bowel syndrome with intestinal failure. It might restore intestinal structural and functional integrity. Our patient endured a surgical resection ought to superior mesenteric artery thrombosis. In June 2016 started treatment with teduglutide. It has decreased the daily parenteral nutrition and fluids requirements in volume and time. It has reduced in a 53% (from baseline 1,590 ml to 840 ml) the parenteral nutrition volume and a 38% (from baseline 2,000 ml to 1,250 ml) the fluids support. It has also reduced the time of parenteral support in seven hours. The patient increased his weight and quality of life during the treatment.

FLUID-THERAPY – PARENTERAL NUTRITION – TEDUGLUTIDE



Fill out the form below to buy this article

Name and surname:

DNI/NIF ID/VAT IDENTIFICATION No.:

Contact Email:

Phone:

Address:

Zip code:

City:

Province:

Country:

*I have read and accept the privacy policy
Price : 30,25